Radiotherapy for recurrent prostate cancer

2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group

Hester Lieng, Amy J. Hayden, David R.H. Christie, Brian J. Davis, Thomas N. Eade, Louise Emmett, Tanya Holt, George Hruby, David Pryor, Thomas P. Shakespeare, Mark Sidhom, Marketa Skala, Kirsty Wiltshire, John Yaxley, Andrew Kneebone

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The management of patients with biochemical, local, nodal, or oligometastatic relapsed prostate cancer has become more challenging and controversial. Novel imaging modalities designed to detect recurrence are increasingly used, particularly PSMA-PET scans in Australia, New Zealand and some European countries. Imaging techniques such as MRI and PET scans using other prostate cancer-specific tracers are also being utilised across the world. The optimal timing for commencing salvage treatment, and the role of local and/or systemic therapies remains controversial. Through surveys of the membership, the Australian and New Zealand Faculty of Radiation Oncology Genito-Urinary Group (FROGG) identified wide variation in the management of recurrent prostate cancer. Following a workshop conducted in April 2017, the FROGG management committee reviewed the literature and developed a set of recommendations based on available evidence and expert opinion, for the appropriate investigation and management of recurrent prostate cancer. These recommendations cover the role and timing of post-prostatectomy radiotherapy, the management of regional nodal metastases and oligometastases, as well as the management of local prostate recurrence after definitive radiotherapy.

Original languageEnglish (US)
JournalRadiotherapy and Oncology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Radiation Oncology
New Zealand
Prostatic Neoplasms
Radiotherapy
Positron-Emission Tomography
Recurrence
Salvage Therapy
Expert Testimony
Prostatectomy
Prostate
Magnetic Resonance Imaging
Neoplasm Metastasis
Education
Therapeutics

Keywords

  • Oligometastases
  • Prostatectomy
  • PSMA-PET
  • Relapse
  • Salvage
  • SBRT

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Radiotherapy for recurrent prostate cancer : 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. / Lieng, Hester; Hayden, Amy J.; Christie, David R.H.; Davis, Brian J.; Eade, Thomas N.; Emmett, Louise; Holt, Tanya; Hruby, George; Pryor, David; Shakespeare, Thomas P.; Sidhom, Mark; Skala, Marketa; Wiltshire, Kirsty; Yaxley, John; Kneebone, Andrew.

In: Radiotherapy and Oncology, 01.01.2018.

Research output: Contribution to journalArticle

Lieng, H, Hayden, AJ, Christie, DRH, Davis, BJ, Eade, TN, Emmett, L, Holt, T, Hruby, G, Pryor, D, Shakespeare, TP, Sidhom, M, Skala, M, Wiltshire, K, Yaxley, J & Kneebone, A 2018, 'Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group', Radiotherapy and Oncology. https://doi.org/10.1016/j.radonc.2018.06.027
Lieng, Hester ; Hayden, Amy J. ; Christie, David R.H. ; Davis, Brian J. ; Eade, Thomas N. ; Emmett, Louise ; Holt, Tanya ; Hruby, George ; Pryor, David ; Shakespeare, Thomas P. ; Sidhom, Mark ; Skala, Marketa ; Wiltshire, Kirsty ; Yaxley, John ; Kneebone, Andrew. / Radiotherapy for recurrent prostate cancer : 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. In: Radiotherapy and Oncology. 2018.
@article{b5dd854470f44d24a58b04e64dc8104a,
title = "Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group",
abstract = "The management of patients with biochemical, local, nodal, or oligometastatic relapsed prostate cancer has become more challenging and controversial. Novel imaging modalities designed to detect recurrence are increasingly used, particularly PSMA-PET scans in Australia, New Zealand and some European countries. Imaging techniques such as MRI and PET scans using other prostate cancer-specific tracers are also being utilised across the world. The optimal timing for commencing salvage treatment, and the role of local and/or systemic therapies remains controversial. Through surveys of the membership, the Australian and New Zealand Faculty of Radiation Oncology Genito-Urinary Group (FROGG) identified wide variation in the management of recurrent prostate cancer. Following a workshop conducted in April 2017, the FROGG management committee reviewed the literature and developed a set of recommendations based on available evidence and expert opinion, for the appropriate investigation and management of recurrent prostate cancer. These recommendations cover the role and timing of post-prostatectomy radiotherapy, the management of regional nodal metastases and oligometastases, as well as the management of local prostate recurrence after definitive radiotherapy.",
keywords = "Oligometastases, Prostatectomy, PSMA-PET, Relapse, Salvage, SBRT",
author = "Hester Lieng and Hayden, {Amy J.} and Christie, {David R.H.} and Davis, {Brian J.} and Eade, {Thomas N.} and Louise Emmett and Tanya Holt and George Hruby and David Pryor and Shakespeare, {Thomas P.} and Mark Sidhom and Marketa Skala and Kirsty Wiltshire and John Yaxley and Andrew Kneebone",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.radonc.2018.06.027",
language = "English (US)",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Radiotherapy for recurrent prostate cancer

T2 - 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group

AU - Lieng, Hester

AU - Hayden, Amy J.

AU - Christie, David R.H.

AU - Davis, Brian J.

AU - Eade, Thomas N.

AU - Emmett, Louise

AU - Holt, Tanya

AU - Hruby, George

AU - Pryor, David

AU - Shakespeare, Thomas P.

AU - Sidhom, Mark

AU - Skala, Marketa

AU - Wiltshire, Kirsty

AU - Yaxley, John

AU - Kneebone, Andrew

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The management of patients with biochemical, local, nodal, or oligometastatic relapsed prostate cancer has become more challenging and controversial. Novel imaging modalities designed to detect recurrence are increasingly used, particularly PSMA-PET scans in Australia, New Zealand and some European countries. Imaging techniques such as MRI and PET scans using other prostate cancer-specific tracers are also being utilised across the world. The optimal timing for commencing salvage treatment, and the role of local and/or systemic therapies remains controversial. Through surveys of the membership, the Australian and New Zealand Faculty of Radiation Oncology Genito-Urinary Group (FROGG) identified wide variation in the management of recurrent prostate cancer. Following a workshop conducted in April 2017, the FROGG management committee reviewed the literature and developed a set of recommendations based on available evidence and expert opinion, for the appropriate investigation and management of recurrent prostate cancer. These recommendations cover the role and timing of post-prostatectomy radiotherapy, the management of regional nodal metastases and oligometastases, as well as the management of local prostate recurrence after definitive radiotherapy.

AB - The management of patients with biochemical, local, nodal, or oligometastatic relapsed prostate cancer has become more challenging and controversial. Novel imaging modalities designed to detect recurrence are increasingly used, particularly PSMA-PET scans in Australia, New Zealand and some European countries. Imaging techniques such as MRI and PET scans using other prostate cancer-specific tracers are also being utilised across the world. The optimal timing for commencing salvage treatment, and the role of local and/or systemic therapies remains controversial. Through surveys of the membership, the Australian and New Zealand Faculty of Radiation Oncology Genito-Urinary Group (FROGG) identified wide variation in the management of recurrent prostate cancer. Following a workshop conducted in April 2017, the FROGG management committee reviewed the literature and developed a set of recommendations based on available evidence and expert opinion, for the appropriate investigation and management of recurrent prostate cancer. These recommendations cover the role and timing of post-prostatectomy radiotherapy, the management of regional nodal metastases and oligometastases, as well as the management of local prostate recurrence after definitive radiotherapy.

KW - Oligometastases

KW - Prostatectomy

KW - PSMA-PET

KW - Relapse

KW - Salvage

KW - SBRT

UR - http://www.scopus.com/inward/record.url?scp=85050122602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050122602&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2018.06.027

DO - 10.1016/j.radonc.2018.06.027

M3 - Article

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

ER -